• Contact us: 01476 247 007
    PDSlogo1PDSlogo1PDSlogo1PDSlogo1
    • How can we help
      • Pharmacovigilance
        • National contact person for pharmacovigilance – post Brexit
        • Pharmacovigilance Standard Operating Procedure Audits
        • Post Marketing Pharmacovigilance Support
        • Clinical Trial Pharmacovigilance Support
        • EU QPPV Provision
        • Quality & Compliance
        • Risk Assessment and Management
        • Signal Detection and Management
      • Medical Writing
      • Patient Information
      • Regulatory
      • Market Authorisation Holding
    • Brexit
    • Our Partners
      • Marti Farm
      • Affiliates
      • Medilink
      • External Team
    • News
    • Get in touch
    ✕
    • Filter by
    • Categories
    • Tags
    • Authors
    • Show all
    • All
    • Brexit Updates
    • Industry News
    • NCPP
    • Patient Information
    • PDS News
    • Pharmacovigilance
    • Risk Management
    • All
    • Aimovig
    • BioCity
    • brexit ready
    • Brexit updates
    • British Association for the Study of Headache
    • CGRP
    • chronic migraine
    • coronavirus
    • COVID-19
    • Deputy QPPV for Pharmacovigilance
    • EMA latest guidance
    • erenumab
    • EU MA
    • EU QPPV
    • EU QPPV for Pharmacovigilance
    • EU/EEA QPPV
    • European Marketing Authorisation Holders (MAH)
    • GCP inspections
    • Good Clinical Practice inspections
    • MAH Service
    • Marketing Authorisation Holders
    • medilink east midlands business awards
    • MHRA latest guidance
    • MHRA post-transition period information
    • National Contact Person for Pharmacovigilance (NCPP)
    • NICE agrees to look again at Novartis’ Aimovig for migraine prevention
    • Novartis
    • Outstanding Achievement Award
    • Periodic Safety Update Reports
    • Pharmaceutical administration services
    • pharmacovigilance
    • Pharmacovigilance (QPPV)
    • Pharmacovigilance (QPPV) provision post-Brexit
    • Post-Authorisation Safety Studies-protocols and final study reports
    • PSMF (pharmacovigilance system master file)
    • Pure Drug Safety
    • QPPV (Qualified Person for Pharmacovigilance)
    • QPPVs based in the UK
    • Quality and compliance
    • Regulatory services
    • remain compliant in the UK
    • Responsible Person for Eudravigilance in clinical trials
    • Risk Management Plans
    • severe migraine
    • summer intern
    • Sygnature Discovery
    • the transition period for Pharmacovigilance and Regulatory
    • UK and non-UK Individual Case Safety Reports
    • UK QPPV
    • All
    • bone
    • Liselle Barnsley
    12th February 2020
    What happens after Brexit for Pharmacovigilance and Regulatory?
    12th February 2020

    What happens after Brexit for Pharmacovigilance and Regulatory?

    Do you like it?
    Read more
    15th January 2020
    15th January 2020

    Is your pharmaceutical company Brexit ready?

    Pure Drug Safety is ready to help you with your post Brexit pharmacovigilance and regulatory requirements – deal or no deal. Just call us now for […]
    Do you like it?
    Read more

    PLEASE NOTE OUR NEW PHONE NUMBER AS OF 1st JUNE 2021
    Call our team +44(0) 1476 247 007
    email info@puredrugsafety.com



    Sign up for our newsletter

    © 2019 - 2023 Pure Drug Safety.
    As of 1st June 2021 NEW OFFICE & REGISTERED ADDRESS: BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, UK
    Pure Drug Safety Limited is a company registered in England and Wales. Registered Company Number 7702236. VAT Registered Number 117 966 288
    For our GDPR and Privacy Policy click here
    Built + Hosted by GIGER MEDIA | Designed by Gather Creative | Content managed by Tailored Marketing Solutions